Denali Therapeutics Inc.

Denali Therapeutics develops the TransportVehicle platform, which uses engineered Fc domains to deliver antibodies, enzymes, and oligonucleotides across the blood-brain barrier for central nervous system diseases via receptor-mediated transcytosis.